Last reviewed · How we verify

KEMRI-Wellcome Trust Collaborative Research Program — Portfolio Competitive Intelligence Brief

KEMRI-Wellcome Trust Collaborative Research Program pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
hepatitis A vaccine, DTaP, PCV10 hepatitis A vaccine, DTaP, PCV10 marketed combination vaccine Immunology
PCV10 and DTaP PCV10 and DTaP marketed vaccine Immunology
Benzyl penicillin Benzyl penicillin phase 3 Beta-lactam antibiotic Penicillin-binding proteins (PBPs) Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University of Oxford · 3 shared drug classes
  2. Pfizer Inc. · 2 shared drug classes
  3. GlaxoSmithKline · 2 shared drug classes
  4. National Taiwan University Hospital · 2 shared drug classes
  5. Pfizer · 2 shared drug classes
  6. Radboud University Medical Center · 2 shared drug classes
  7. Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
  8. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for KEMRI-Wellcome Trust Collaborative Research Program:

Cite this brief

Drug Landscape (2026). KEMRI-Wellcome Trust Collaborative Research Program — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kemri-wellcome-trust-collaborative-research-program. Accessed 2026-05-16.

Related